Skip to main content

Oxidative Stress

5
Pipeline Programs
10
Companies
47
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
3
0
0
1
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

Takeda
DUETACTApproved
pioglitazone and glimepiride
Takeda
Sulfonylurea [EPC]oral2006

Competitive Landscape

10 companies ranked by most advanced pipeline stage

Takeda
TakedaTOKYO, Japan
1 program
1
DUETACT(Pioglitazone)PHASE_25 trials
Active Trials
NCT03501277Completed72Est. Jul 2018
NCT02823808Unknown96Est. Dec 2021
NCT02989649Terminated593Est. Jan 2018
+2 more trials
Human BioSciences
Human BioSciencesWV - Martinsburg
2 programs
1
Oxytocin nasal sprayPhase 2
Titration of oxygen during neonatal resuscitationN/A1 trial
Active Trials
NCT03115463Completed75Est. Sep 2022
Medica Corp
Medica CorpMA - Bedford
1 program
1
Angiotensin converting enzyme inhibitorPhase 21 trial
Active Trials
NCT05232370Completed39Est. Jan 2022
Cognition Therapeutics
Cognition TherapeuticsPA - Pittsburgh
1 program
1
Oxytocin nasal sprayPhase 21 trial
Active Trials
NCT04732247Completed40Est. Sep 2023
Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
1
6 mg xanthohumol per dayPhase 11 trial
Active Trials
NCT02432651Completed64Est. Jun 2017
Lonza
LonzaBasel, Switzerland
3 programs
Cross Training CourseN/A1 trial
OceanixN/A1 trial
Oceanix®N/A1 trial
Active Trials
NCT04314596Completed18Est. Feb 2020
NCT04136821Completed25Est. Jan 2020
NCT04315077Completed22Est. Nov 2019
Forte Biosciences
1 program
MilkN/A1 trial
Active Trials
NCT03821116Completed84Est. Jun 2020
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
Normal Values of Oxidative Stress, Taurine, and Related MarkersN/A1 trial
Active Trials
NCT02649777Completed22Est. Dec 2017
Defence Therapeutics
Defence TherapeuticsBC - Vancouver
1 program
OxygenN/A1 trial
Active Trials
NCT02577692Unknown20Est. Nov 2019
Genomics
GenomicsUK - Oxford
1 program
Oxytocin nasal sprayPHASE_2

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
TakedaPioglitazone
TakedaPioglitazone
TakedaPioglitazone
TakedaPioglitazone
TakedaPioglitazone
TakedaPioglitazone
TakedaPioglitazone
TakedaPioglitazone
TakedaPioglitazone
TakedaPioglitazone
TakedaPioglitazone
TakedaPioglitazone
TakedaPioglitazone
TakedaPioglitazone
TakedaPioglitazone

Showing 15 of 47 trials with date data

Clinical Trials (47)

Total enrollment: 226,827 patients across 47 trials

NCT02823808TakedaPioglitazone

Effect of Alogliptin/Pioglitazone on the Preservation of Long-term Beta-cell Function

Start: Jul 2017Est. completion: Dec 202196 patients
Phase 4Unknown
NCT02763007TakedaPioglitazone

An Extension Study of PEAK Trial

Start: May 2016Est. completion: Feb 201941 patients
Phase 4Terminated
NCT00835120TakedaPioglitazone

Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance

Start: Mar 2009Est. completion: Apr 201334 patients
Phase 4Completed
NCT00770835TakedaPioglitazone

Efficacy and Safety of Pioglitazone in Treating Subjects With Vascular Complications Associated With Type 2 Diabetes Mellitus.

Start: Mar 2009Est. completion: May 201139 patients
Phase 4Completed
NCT00770445TakedaPioglitazone

Efficacy of Pioglitazone and Metformin on Cardiovascular Risk in Subjects With Insulin-Treated Type 2 Diabetes Mellitus.

Start: May 2008Est. completion: Jul 2010121 patients
Phase 4Completed
NCT01588470TakedaPioglitazone

Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM)

Start: Jun 2006Est. completion: Dec 2011130 patients
Phase 4Completed
NCT00672919TakedaPioglitazone

Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.

Start: Nov 2003Est. completion: Aug 2004305 patients
Phase 4Completed
NCT00816218TakedaPioglitazone

Molecular Mechanisms of Type 2 Diabetes Mellitus

Start: Mar 2003Est. completion: Nov 200839 patients
Phase 4Completed
NCT00494312TakedaPioglitazone

Safety Study of Pioglitazone Compared To Glyburide on Liver Function

Start: Oct 2000Est. completion: Jun 20052,120 patients
Phase 4Completed
NCT01156597TakedaPioglitazone

Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes

Start: Apr 2008Est. completion: Sep 201030 patients
Phase 3Completed
NCT00727857TakedaPioglitazone

Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.

Start: Jun 2007Est. completion: Aug 2008600 patients
Phase 3Completed
NCT00770653TakedaPioglitazone

Efficacy of Pioglitazone/Metformin Combination Therapy in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia.

Start: Apr 2007Est. completion: May 2009305 patients
Phase 3Completed
NCT00772174TakedaPioglitazone

Efficacy and Safety Study of Pioglitazone Combined With Metformin on Metabolic Syndrome in Subjects With Type 2 Diabetes

Start: Jan 2007Est. completion: Feb 2008418 patients
Phase 3Completed
NCT00770952TakedaPioglitazone

Efficacy of Pioglitazone and Glimepiride Combination Therapy in Treating Subjects With Type 2 Diabetes Mellitus.

Start: Dec 2006Est. completion: Dec 200891 patients
Phase 3Completed
NCT00376181TakedaPioglitazone

Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus

Start: Jun 2006Est. completion: May 200796 patients
Phase 3Terminated
NCT00225264TakedaPioglitazone

Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease.

Start: Oct 2003Est. completion: May 2006458 patients
Phase 3Completed
NCT00521742TakedaPioglitazone

Efficacy of Pioglitazone Compared to Glyburide in Treating Subjects With Type 2 Diabetes Mellitus and Mild Cardiac Disease

Start: Mar 2001Est. completion: Jan 2003300 patients
Phase 3Completed
NCT01318122TakedaPioglitazone

Long-term Safety Study of Alogliptin Used in Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan

Start: May 2008Est. completion: Aug 2009336 patients
Phase 2/3Completed
NCT01318070TakedaPioglitazone

Efficacy and Safety of Alogliptin Used Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan

Start: Nov 2007Est. completion: Oct 2008339 patients
Phase 2/3Completed

Oxytocin for Oxidative Stress and Inflammation

Start: Feb 2022Est. completion: Sep 202340 patients
Phase 2Completed
NCT05232370Medica CorpAngiotensin converting enzyme inhibitor

The Effect of Enalapril, Losartan or Not Antihypertensive on the Oxidative Status in Renal Transplant Recipients

Start: Jan 2022Est. completion: Jan 202239 patients
Phase 2Completed
NCT00770640TakedaPioglitazone

Efficacy of Pioglitazone and Insulin in Treating Subjects With Type 2 Diabetes Mellitus and Renal Failure.

Start: Aug 2008Est. completion: Jun 201040 patients
Phase 2Completed
NCT00770497TakedaPioglitazone

Efficacy Study of Pioglitazone and Ramipril Combination Therapy in Treating Non-diabetic Hypertensive Patients.

Start: Mar 2007Est. completion: May 2008172 patients
Phase 2Completed
NCT00771004TakedaPioglitazone

Efficacy of Pioglitazone on Myocardial Function in Patients Undergoing Coronary Stent Implantation.

Start: Aug 2006Est. completion: Feb 200963 patients
Phase 2Completed
NCT00770575TakedaPioglitazone

Efficacy Study of Pioglitazone and Atorvastatin Combination Therapy in Treating Subjects With Elevated Risk for Cardiovascular Disease

Start: Jun 2005Est. completion: Oct 2006148 patients
Phase 2Completed
NCT03501277TakedaPioglitazone

A Study to Determine the Bioequivalence of Alogliptin and Pioglitazone When Administered as Individual Tablets and as Fixed-Dose Combination (FDC)-SYR-322-4833 BL Tablets to Healthy Russian Participants

Start: May 2018Est. completion: Jul 201872 patients
Phase 1Completed
NCT02432651Oregon Therapeutics6 mg xanthohumol per day

Xanthohumol and Prevention of DNA Damage

Start: Mar 2015Est. completion: Jun 201764 patients
Phase 1Completed
NCT04314596LonzaCross Training Course

The Effects of Antioxidant Supplementation on Multiple Endurance Race Performance, Physiology, and Recovery.

Start: Jan 2020Est. completion: Feb 202018 patients
N/ACompleted

The Short Term Effects of Oceanix Supplementation on Recovery

Start: Oct 2019Est. completion: Nov 201922 patients
N/ACompleted

The Long-term Effects of Oceanix™ on Resistance Training Adaptations

Start: Sep 2019Est. completion: Jan 202025 patients
N/ACompleted

Milk and Soured Milk (filmjölk) Intervention on Oxidative Stress and Inflammation

Start: Jan 2019Est. completion: Jun 202084 patients
N/ACompleted
NCT03115463Human BioSciencesTitration of oxygen during neonatal resuscitation

Saturation Targets and Resuscitation in Preterm Trial

Start: Sep 2017Est. completion: Sep 202275 patients
N/ACompleted
NCT02989649TakedaPioglitazone

Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice

Start: Dec 2016Est. completion: Jan 2018593 patients
N/ATerminated

Inspired Oxygen on Oxidative Stress and Breath Volatile Organic Compound Composition in Healthy Volunteers

Start: May 2016Est. completion: Nov 201920 patients
N/AUnknown
NCT02649777Colorado TherapeuticsNormal Values of Oxidative Stress, Taurine, and Related Markers

Normal Values of Oxidative Stress, Taurine, and Related Markers

Start: Jan 2016Est. completion: Dec 201722 patients
N/ACompleted
NCT01990300TakedaPioglitazone

Alogliptin/Pioglitazone (Liovel) Combination Tablets Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus

Start: Nov 2011Est. completion: Mar 20153,281 patients
N/ACompleted
NCT02098733TakedaPioglitazone

Long-term Use of Sonias Combination Tablets in Patients With Type 2 Diabetes Mellitus

Start: Jun 2011Est. completion: May 20141,168 patients
N/ACompleted
NCT02098746TakedaPioglitazone

Pioglitazone/Glimepiride (Sonias) Combination Tablets Special Drug Use Surveillance Survey in Patients With Type 2 Diabetes Mellitus Who Respond Poorly to Pioglitazone

Start: Jun 2011Est. completion: Jul 2014294 patients
N/ACompleted
NCT02024971TakedaPioglitazone

Special Drug Use Surveillance of Pioglitazone/Metformin Hydrochloride Combination Tablets Survey on Long-term Use for Type 2 Diabetes Mellitus

Start: Jul 2010Est. completion: Nov 20131,103 patients
N/ACompleted
NCT01023620TakedaPioglitazone

HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone)

Start: Oct 2009Est. completion: May 20104 patients
N/ACompleted
NCT02068508TakedaPioglitazone

Pioglitazone Tablets Special Drug Use Surveillance "Combined Use of Insulin Products / Long-term Treatment"

Start: Jul 2009Est. completion: Jun 20141,067 patients
N/ACompleted
NCT02003014TakedaPioglitazone

Pioglitazone Tablets Special Drug Use Surveillance "Combined Use of Biguanides / Long-term Treatment"

Start: Feb 2009Est. completion: Jan 2012899 patients
N/ACompleted
NCT02181842TakedaPioglitazone

Pioglitazone Tablets Specified Drug-use Survey <Survey on Glycemic Control in Type 2 Diabetic Patients With a History of Cerebral Infarction>

Start: Jan 2009Est. completion: Jun 2011246 patients
N/ACompleted
NCT01165190TakedaPioglitazone

Effect of Pioglitazone on Mitochondrial Function in Muscle and Adipose Tissue in Humans

Start: May 2008Est. completion: May 201020 patients
N/ACompleted
NCT02002975TakedaPioglitazone

Pioglitazone Special Drug Use Surveillance "Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus"

Start: Oct 2007Est. completion: Jun 201318,223 patients
N/ACompleted
NCT00159211TakedaPioglitazone

Abdominal Adipose Tissue Distribution in Type 2 Diabetic Patients Treated During 6 Months With Pioglitazone or Insulin

Start: May 2005Est. completion: May 200728 patients
N/ATerminated
NCT01637935TakedaPioglitazone

Cohort Study of Pioglitazone and Bladder Cancer in Patients With Type II Diabetes

Start: Jul 2004Est. completion: Aug 2014193,099 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

10 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.